Thi-Sau Migone, Jacques Gaudreault and Jan-Willem Theunissen (2020, September)

ICON-2, a Tissue Factor–Targeted Antibody-Drug Conjugate for the Treatment of Solid Tumors

Poster Presented at The World ADC Digital Conference.

Jan-Willem Theunissen, Allen G Cai, Maryam M Bhatti, Anthony B Cooper, Andrew D Avery, Ryan Dorfman, Sebastian Guelman, Zoia Levashova and Thi-Sau Migone.

Treating Tissue Factor-Positive Cancers With Antibody-Drug Conjugates That Do Not Affect Blood Clotting.
Mol Cancer Ther August 20 2018 DOI:10.1158/1535-7163.MCT-18-0471.

William Greene, Grazia Spiga, Brian C. Gilger, David Culp, Thi-Sau Migone (2018, April)

Activity of anti-Tissue Factor fusion protein ICON-1 in a swine model of choroidal neovascularization. 
Poster Presented at The Association for Research in Vision and Ophthalmology, Honolulu, HI.

Gabriela Burian, Jacques Gaudreault, Brian C. Gilger, David Culp, Thi-Sau Migone (2018, April)

ICON-1 Pharmacokinetics after intravitreal and intravenous administration to rabbits. 
Poster Presented at The Association for Research in Vision and Ophthalmology, Honolulu, HI.

Wells JA, Berger BB, Gonzales C, Gonzales VH, Johnson DL, Sippy BD, Soni M.

Multicenter phase 1 clinical trial targeting tissue factor for the treatment of neovascular AMD.
Invest Ophthalmol Vis Sci 2012;53: E-Abstract 450.

Cocco E, Varughese J, Buza N, Bellone S, Lin KY, Bellone M, Todeschini P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Carrara L, Tassi R, Pecorelli S, Lockwood CJ, Santin AD.

Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.
Clin Exp Metastasis. 2011 Oct;28(7):689-700.

Hu Z, Li J.

Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer.
BMC Immunol. 2010 Oct 12;11:49.

Krikun G, Hu Z, Osteen K, Bruner-Tran KL, Schatz F, Taylor HS, Toti P, Arcuri F, Konigsberg W, Garen A, Booth CJ, Lockwood CJ.

The immunoconjugate “icon” targets aberrantly expressed endothelial tissue factor causing regression of endometriosis.
Am J Pathol. 2010 Feb;176(2):1050-6.

Tezel TH, Bodek E, Sönmez K, Kaliappan S, Kaplan HJ, Hu Z, Garen A.

Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of factor VII-Fc chimeric antibody.
Ocul Immunol Inflamm. 2007 Jan-Feb;15(1):3-10.

Bora PS, Hu Z, Tezel TH, Sohn JH, Kang SG, Cruz JM, Bora NS, Garen A, Kaplan HJ.

Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration.
Proc Natl Acad Sci USA. 2003 Mar 4;100(5):2679-84.

Hu Z, Garen A.

Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer.
Proc Natl Acad Sci USA. 2001 Oct 9;98(21):12180-5.

Hu Z, Garen A.

Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy.
Proc Natl Acad Sci USA. 2000 Aug 1;97(16):9221-5.

Wang B, Chen YB, Ayalon O, Bender J, Garen A.

Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement.
Proc Natl Acad Sci USA. 1999 Feb 16;96(4):1627-32.